Is Sanofi (SNY) One of the Best Healthcare Stocks Under $50 to Invest In?

Sanofi (NASDAQ:SNY) is one of the best healthcare stocks under $50 to invest in. Kepler Capital maintained a Hold on Sanofi (NASDAQ:SNY) on February 3 with a price target of €85. The same day, Sanofi (NASDAQ:SNY) announced plans to execute a share buyback program of €1 billion in 2026, entering into a mandate with an investment service provider for the program on February 2. The terms of the mandate stipulate that Sanofi (NASDAQ:SNY) will repurchase its own shares for a total consideration of up to €1 billion, at the latest between February 3 and December 31.

Is Sanofi (SNY)the Best Gene-Editing Stock to Buy?

In a separate development, Sanofi (NASDAQ:SNY) announced positive results for the LEAP2MONO phase 3 study on February 2, stating that venglustat met the primary and three out of four key secondary endpoints in adults and pediatric patients 12 years and older with neurological manifestations of type 3 Gaucher disease, which is a rare lysosomal storage disorder. Sanofi (NASDAQ:SNY) clarified that Venglustat is an investigational glucosylceramide synthase inhibitor (GCSi) that works by bringing down the abnormal accumulation of sugar-and-fat molecules in cells and organs.

Sanofi (NASDAQ:SNY) researches, produces, and distributes pharmaceutical products. The company’s operations are divided into the Pharmaceuticals, Consumer Healthcare, and Vaccines segments.

While we acknowledge the potential of XXXX to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than XXXX and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.